One Lambda, Luminex renew 10-year human leukocyte antigen technology development partnership

One Lambda Inc., a leading manufacturer and supplier of quality products and technology for the HLA transplant community, and Luminex Corporation have agreed to a long-term renewal of their 10-year strategic partnership aimed at developing platforms and technologies for human leukocyte antigen (HLA).

“One Lambda and Luminex combined the power of Luminex's xMAP Technology with One Lambda's expertise in HLA testing and organ transplantation to dramatically advance the care available to those undergoing transplants”

Effective diagnostics are essential in transplant medicine. HLA typing and antibody screening are critical in matching organ donors and organ recipients, minimizing rejection and maintaining transplant patients' long-term health following a transplant. This kind of testing can require screening a patient for hundreds of HLA markers and antibodies.

One Lambda has developed a range of assays, based on Luminex's xMAP^® Technology, that have streamlined transplant diagnostics. The xMAP platform allows multiple, simultaneous tests to be run on a single sample. This proved to be an ideal fit for transplant testing. One Lambda's LABType^® SSO and LABScreen^® products can detect up to 500 HLA specificities in a single test, eliminating the need to run multiple tests. One Lambda's xMAP-based assays are used in more than 80 countries worldwide.

"One Lambda and Luminex combined the power of Luminex's xMAP Technology with One Lambda's expertise in HLA testing and organ transplantation to dramatically advance the care available to those undergoing transplants," said George Ayoub, president and CEO of One Lambda. "Our platforms have significantly enhanced healthcare providers' ability to care for organ transplant patients by delivering vital information that helps them to better match donors with recipients."

One Lambda's dedication to innovation and quality ensures that One Lambda is continually enhancing and expanding their product menu to improve the quality of life for transplant patients. Their products are continually updated with the latest donor registry data and new DNA genotypes.

"Luminex and One Lambda have set the standard for strategic partnership with our collaboration that has delivered new technology and transformed the practice of transplantation medicine," said Patrick J. Balthrop, president and CEO of Luminex. "One Lambda has an impressive history of innovation in the field of transplantation, and we expect that our work together will continue to deliver significant technology advances and market leadership into the next decade."